These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20410329

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
    Shearer JD, Vassar ML, Swiderski W, Metcalfe K, Niemuth N, Henderson I.
    Vaccine; 2010 Oct 21; 28(45):7313-8. PubMed ID: 20816903
    [Abstract] [Full Text] [Related]

  • 5. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.
    Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R.
    Clin Vaccine Immunol; 2013 Aug 21; 20(8):1266-73. PubMed ID: 23761665
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component.
    Mahmut N, Inoue K, Fujinaga Y, Arimitsu H, Sakaguchi Y, Hughes L, Hirst R, Murphy T, Tsuji T, Watanabe T, Ohyama T, Karasawa T, Nakamura S, Yokota K, Oguma K.
    J Med Microbiol; 2002 Oct 21; 51(10):813-820. PubMed ID: 12435059
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alternative vaccination against equine botulism (BoNT/C).
    Frey J, Eberle S, Stahl C, Mazuet C, Popoff M, Schatzmann E, Gerber V, Dungu B, Straub R.
    Equine Vet J; 2007 Nov 21; 39(6):516-20. PubMed ID: 18065309
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
    Shi DY, Chen BY, Mao YY, Zhou G, Lu JS, Yu YZ, Zhou XW, Sun ZW.
    Hum Vaccin Immunother; 2019 Nov 21; 15(3):755-760. PubMed ID: 30433836
    [Abstract] [Full Text] [Related]

  • 13. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y, Shi D, Liu S, Gong ZW, Wang S, Sun Z.
    Hum Vaccin Immunother; 2015 Nov 21; 11(2):468-73. PubMed ID: 25483668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B.
    Ponmariappan S, Jain S, Sijoria R, Tomar A, Kumar O.
    Protein Pept Lett; 2012 Mar 21; 19(3):288-98. PubMed ID: 21933129
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM, Motter RN, Arnon SS.
    Vaccine; 2018 Apr 05; 36(15):2041-2048. PubMed ID: 29475762
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
    Sharma R, Zhao H, Al-Saleem FH, Ubaid AS, Puligedda RD, Segan AT, Lindorfer MA, Bermudez R, Elias M, Adekar SP, Simpson LL, Taylor RP, Dessain SK.
    Mol Immunol; 2014 Feb 05; 57(2):247-54. PubMed ID: 24184879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.